Mauricio J. Reginato

Dr. Mauricio J. Reginato

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2019 in BMC Biology
Verified
Journal Article
Open access
PDF file
NANeha M. Akella
Neha M. Akella
LCLorela Ciraku
Lorela Ciraku
MRMauricio J. Reginato
Mauricio J. Reginato
Altered metabolism and deregulated cellular energetics are now considered a hallmark of all cancers. Glucose, glutamine, fatty acids, and amino acids are the primary drivers of tumor growth and act as substrates for the hexosamine biosynthetic pathway (HBP). The HBP culminates in the production of an amino sugar uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) that, along with other charged nucleotide sugars, serves as the basis for biosynthesis of glycoproteins and other glycoconjugates. These nutrient-driven post-translational modifications are highly altered in cancer and regulate protein functions in various cancer-associated processes. In this review, we discuss recent progress in understanding the mechanistic relationship between the HBP and cancer.

12 October 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GMGiang Le Minh
Giang Le Minh
EEEmily M. Esquea
Emily M. Esquea
RYRiley G. Young
Riley G. Young
JHJessie Huang
Jessie Huang
MRMauricio J. Reginato
Mauricio J. Reginato
Recent advances in the understanding of the molecular mechanisms underlying cancer progression have led to the development of novel therapeutic targeting strategies. Aberrant glycosylation patterns and their implication in cancer have gained increasing attention as potential targets due to the critical role of glycosylation in regulating tumor-specific pathways that contribute to cancer cell survival, proliferation, and progression. A special type of glycosylation that has been gaining momentum in cancer research is the modification of nuclear, cytoplasmic, and mitochondrial proteins, termed O-GlcNAcylation. This protein modification is catalyzed by an enzyme called O-GlcNAc transferase (OGT), which uses the final product of the Hexosamine Biosynthetic Pathway (HBP) to connect altered nutrient availability to changes in cellular signaling that contribute to multiple aspects of tumor progression. Both O-GlcNAc and its enzyme OGT are highly elevated in cancer and fulfill the crucial role in regulating many hallmarks of cancer. In this review, we present and discuss the latest findings elucidating the involvement of OGT and O-GlcNAc in cancer.

22 February 2022 in Oncogene
Verified
Journal Article
Closed access
PDF file
LCLorela Ciraku
Lorela Ciraku
ZBZachary A. Bacigalupa
Zachary A. Bacigalupa
JJJing Ju
Jing Ju
RMRebecca A. Moeller
Rebecca A. Moeller
GMGiang Le Minh
Giang Le Minh
MRMauricio J. Reginato
Mauricio J. Reginato

1 April 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
NANeha M. Akella
Neha M. Akella
GMGiang Le Minh
Giang Le Minh
LCLorela Ciraku
Lorela Ciraku
AMAyonika Mukherjee
Ayonika Mukherjee
ZBZachary A. Bacigalupa
Zachary A. Bacigalupa
MRMauricio J. Reginato
Mauricio J. Reginato
Breast tumors are heterogeneous and composed of different subpopulation of cells, each with dynamic roles that can change with stage, site, and microenvironment. Cellular heterogeneity is, in part, due to cancer stem–like cells (CSC) that share properties with stem cells and are associated with treatment resistance. CSCs rewire metabolism to meet energy demands of increased growth and biosynthesis. O-GlcNAc transferase enzyme (OGT) uses UDP-GlcNAc as a substrate for adding O-GlcNAc moieties to nuclear and cytoplasmic proteins. OGT/O-GlcNAc levels are elevated in multiple cancers and reducing OGT in cancer cells blocks tumor growth. Here, we report that breast CSCs enriched in mammosphere cultures contain elevated OGT/O-GlcNAcylation. Inhibition of OGT genetically or pharmacologically reduced mammosphere forming efficiency, the CD44H/CD24L, NANOG+, and ALDH+ CSC population in breast cancer cells. Conversely, breast cancer cells overexpressing OGT increased mammosphere formation, CSC populations in vitro, and also increased tumor initiation and CSC frequency in vivo. Furthermore, OGT regulates expression of a number of epithelial-to-mesenchymal transition and CSC markers including CD44, NANOG, and c-Myc. In addition, we identify Krüppel-like factor 8 (KLF8) as a novel regulator of breast cancer mammosphere formation and a critical target of OGT in regulating CSCs. Implications: These findings demonstrate that OGT plays a key role in the regulation of breast CSCs in vitro and tumor initiation in vivo, in part, via regulation of KLF8, and thus inhibition of OGT may serve as a therapeutic strategy to regulate tumor-initiating activity.

17 November 2021 in Cellular Signalling
Verified
Journal Article
Closed access
LCLorela Ciraku
Lorela Ciraku
EEEmily M. Esquea
Emily M. Esquea
MRMauricio J. Reginato
Mauricio J. Reginato

16 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
EEEmily M. Esquea
Emily M. Esquea
LCLorela Ciraku
Lorela Ciraku
RYRiley G. Young
Riley G. Young
JMJessica Merzy
Jessica Merzy
ATAlexandra N. Talarico
Alexandra N. Talarico
ADAlexej Dick
Alexej Dick
Breast cancer brain metastasis (BCBM) typically results in an end-stage diagnosis and is hindered by a lack of brain-penetrant drugs. Tumors in the brain rely on the conversion of acetate to acetyl-CoA by the enzyme acetyl-CoA synthetase 2 (ACSS2), a key regulator of fatty acid synthesis and protein acetylation. Here, we used a computational pipeline to identify novel brain-penetrant ACSS2 inhibitors combining pharmacophore-based shape screen methodology with absorption, distribution, metabolism, and excretion (ADME) property predictions. We identified compounds AD-5584 and AD-8007 that were validated for specific binding affinity to ACSS2. Treatment of BCBM cells with AD-5584 and AD-8007 leads to a significant reduction in colony formation, lipid storage, acetyl-CoA levels and cell survival in vitro. In an ex vivo brain-tumor slice model, treatment with AD-8007 and AD-5584 reduced pre-formed tumors and synergized with irradiation in blocking BCBM tumor growth. Treatment with AD-8007 reduced tumor burden and extended survival in vivo. This study identifies selective brain-penetrant ACSS2 inhibitors with efficacy towards breast cancer brain metastasis.